Related references
Note: Only part of the references are listed.Emerging Combination Activity and Resistance Profile for Brincidofovir (CMX001) in CMV Prevention and Treatment
S. Foster et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2014)
Selection and Recombinant Phenotyping of a Novel CMX001 and Cidofovir Resistance Mutation in Human Cytomegalovirus
Scott H. James et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation
Francisco M. Marty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy
Sunwen Chou
JOURNAL OF CLINICAL VIROLOGY (2011)
Antiviral Drug Resistance of Human Cytomegalovirus
Nell S. Lurain et al.
CLINICAL MICROBIOLOGY REVIEWS (2010)
Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients
Per Ljungman et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2010)
Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis
Sunwen Chou et al.
TRANSPLANTATION (2010)
Development of CMX001 for the Treatment of Poxvirus Infections
Randall Lanier et al.
VIRUSES-BASEL (2010)
Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro
SL Williams-Aziz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Human cytomegalovirus resistance to antiviral drugs
C Gilbert et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants
E Meijer et al.
CLINICAL MICROBIOLOGY REVIEWS (2003)
Share Paper
